Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Steven Gore

Steven David Gore, MD

Male
Appointment Phone

410-955-8964

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Expertise

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphoblastic Leukemia, Chronic Myeloid Leukemia, General Internal Medicine, Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Research Interests

Drug development in myeloid malignancies; clinical applications of epigenetics

Languages

  • English

Clinical Trial Keywords

  • acute myeloid leukemia
  • acute promyelocytic leukemia
  • myelodysplastic syndrome

Additional Resources

Additional Resources +
  • Education +

    Training

    • Yale University School of Medicine (New Haven CT) (1984)

    Residencies

    • University of Chicago/ Internal Medicine (Chicago IL) (1987)

    Fellowships

    • The Johns Hopkins Hospital/ Oncology (Baltimore MD) (1990)

    Certifications

    • Medical Oncology, American Board of Internal Medicine (1989)
    • Internal Medicine, American Board of Internal Medicine (1987)
  • Research & Publications +

    Selected Publications

    Cheson, B.D.; Greenberg, P.L.; Bennett, J.M.; Lowenberg, B.; Wijermans, P.W.; Nimer, S.D.; Pinto, A.; Beran, M.; de Witte, T.M.; Stone, R.M.; Mittelman, M.; Sanz, G.F.; Gore, S.D.; Schiffer, C.A.; Kantarjian, H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-425.

    Deeg, H.J.; Bowen, D.; Gore, S.D.; Haferlach, T.; Beau, M.M.; Niemeyer, C. Myelodysplastic Syndrome. New York, NY: Springer; 2006.

    Gore, S.D. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan;4(1):83-90.

    Gore, S.D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C.B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J.E.; Rudek, M.A.; Zhao, M.; Smith, B.D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L.J.; Herman, J.G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006 Jun 15;66(12):6361-6369.
    Gore, S.D.; Jones, C.; Kirkpatrick, P. Decitabine. Nat Rev Drug Discov. 2006 Nov;5(11):891-892.

    Greenberg, P.L.; Baer, M.R.; Bennett, J.M.; Bloomfield, C.D.; De Castro, C.M.; Deeg, H.J.; Devetten, M.P.; Emanuel, P.D.; Erba, H.P.; Estey, E.; Foran, J.; Gore, S.D.; Millenson, M.; Navarro, W.H.; Nimer, S.D.; O''Donnell, M.R.; Saba, H.I.; Spiers, K.; Stone, R.M.; Tallman, M.S. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan;4(1):58-77.

    Bagatell, R.; Gore, L.; Egorin, M.J.; Ho, R.; Heller, G.; Boucher, N.; Zuhowski, E.G.; Whitlock, J.A.; Hunger, S.P.; Narendran, A.; Katzenstein, H.M.; Arceci, R.J.; Boklan, J.; Herzog, C.E.; Whitesell, L.; Ivy, S.P.; Trippett, T.M. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007 Mar 15;13(6):1783-1788.

    Carraway, H.E.; Gore, S.D. Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol. 2007 May 20;25(15):1955-1956.

    Fandy, T.E.; Carraway, H.; Gore, S.D. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J. 2007 Jan-Feb;13(1):40-48.

    Fandy, T.E.; Ross, D.D.; Gore, S.D.; Srivastava, R.K. Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL. Cancer Chemother Pharmacol. 2007 Aug;60(3):313-319.

    Gojo, I.; Jiemjit, A.; Trepel, J.B.; Sparreboom, A.; Figg, W.D.; Rollins, S.; Tidwell, M.L.; Greer, J.; Chung, E.J.; Lee, M.J.; Gore, S.D.; Sausville, E.A.; Zwiebel, J.; Karp, J.E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007 Apr 1;109(7):2781-2790.

    Gore, S.D. Intravenous azacitidine for MDS. Clin Adv Hematol Oncol. 2007 Mar;5(3):234.

    Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.; McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15;110(6):1762-1769.

    Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-4473.

    Gore, S.D.; Baylin, S.B.; Herman, J.G. Histone Deacetylase Inhibitors and Demethylating Agents. In: Vincent T. DeVita, J.; Lawrence, T.S.; Rosenberg, S.A., editors. 8e ed. Vol. 8e, Section 11, DeVita, Hellman and Rosenberg''s Cancer: Principles & Practice of Oncology, 8e. York, PA: Lippincott Williams and Wilkins; 2008.

    Gore, S.D.; Hermes-DeSantis, E.R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008 Oct;15 Suppl:40-49.

    Gorelik, B.; Ziv, I.; Shohat, R.; Wick, M.; Hankins, W.D.; Sidransky, D.; Agur, Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res. 2008 Nov 1;68(21):9033-9040.

    Griffiths, E.A.; Gore, S.D. DNA methyltransferase inhibitors: class effect or unique agents? Leuk Lymphoma. 2008 Apr;49(4):650-651.

    Griffiths, E.A.; Gore, S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in hematology. 2008 Jan;45(1):23-30.

    Jiemjit, A.; Fandy, T.E.; Carraway, H.; Bailey, K.A.; Baylin, S.; Herman, J.G.; Gore, S.D. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene. 2008 Jun 5;27(25):3615-3623.

    Karp, J.E.; Smith, B.D.; Gojo, I.; Lancet, J.E.; Greer, J.; Klein, M.; Morris, L.; Levis, M.J.; Gore, S.D.; Wright, J.J.; Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15;14(10):3077-3082.

    Fandy, T.E.; Herman, J.G.; Kerns, P.; Jiemjit, A.; Sugar, E.A.; Choi, S.H.; Yang, A.S.; Aucott, T.; Dauses, T.; Odchimar-Reissig, R.; Licht, J.; McConnell, M.J.; Nasrallah, C.; Kim, M.K.; Zhang, W.; Sun, Y.; Murgo, A.; Espinoza-Delgado, I.; Oteiza, K.; Owoeye, I.; Silverman, L.R.; Gore, S.D.; Carraway, H.E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24;114(13):2764-2773.

    Griffiths, E.A.; Gore, S.D. MicroRNA: mIR-ly regulators of DNMT? Blood. 2009 Jun 18;113(25):6269-6270.

    Karp, J.E.; Flatten, K.; Feldman, E.J.; Greer, J.M.; Loegering, D.A.; Ricklis, R.M.; Morris, L.E.; Ritchie, E.; Smith, B.D.; Ironside, V.; Talbott, T.; Roboz, G.; Le, S.B.; Meng, X.W.; Schneider, P.A.; Dai, N.T.; Adjei, A.A.; Gore, S.D.; Levis, M.J.; Wright, J.J.; Garrett-Mayer, E.; Kaufmann, S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14;113(20):4841-4852.

    Lin, J.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-6249.

    Ye, Y.; McDevitt, M.A.; Guo, M.; Zhang, W.; Galm, O.; Gore, S.D.; Karp, J.E.; Maciejewski, J.P.; Kowalski, J.; Tsai, H.L.; Gondek, L.P.; Tsai, H.C.; Wang, X.; Hooker, C.; Smith, B.D.; Carraway, H.E.; Herman, J.G. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009 Nov 1;69(21):8482-8490.

    Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
    Emadi, A.; Gore, S.D. Arsenic trioxide - An old drug rediscovered. Blood Rev. 2010 Jul-Sep;24(4-5):191-199.

    Gore, S.D.; Gojo, I.; Sekeres, M.A.; Morris, L.; Devetten, M.; Jamieson, K.; Redner, R.L.; Arceci, R.; Owoeye, I.; Dauses, T.; Schachter-Tokarz, E.; Gallagher, R.E. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010 Feb 20;28(6):1047-1053.

    Griffiths, E.A.; Gore, S.D.; Hooker, C.; McDevitt, M.A.; Karp, J.E.; Smith, B.D.; Mohammad, H.P.; Ye, Y.; Herman, J.G.; Carraway, H.E. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010 Sep;51(9):1711-1719

    Griffiths, E.A.; Gore, S.D.; Hooker, C.M.; Mohammad, H.P.; McDevitt, M.A.; Smith, B.D.; Karp, J.E.; Herman, J.G.; Carraway, H.E. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010 Oct 3;5(7 ).

    Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul;34(7):877-882.

    Kasamon, Y.L.; Jones, R.J.; Gocke, C.D.; Blackford, A.L.; Seifter, E.J.; Davis-Sproul, J.M.; Gore, S.D.; Ambinder, R.F. Extended Follow-Up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin''s Lymphomas. Biol Blood Marrow Transplant. 2010 Jul 21.

    Loaiza-Bonilla, A.; Gore, S.D.; Carraway, H.E. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. Curr Opin Hematol. 2010 Mar;17(2):104-109.

    Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.

    Thomas, M.B.; Jaffe, D.; Choti, M.M.; Belghiti, J.; Curley, S.; Fong, Y.; Gores, G.; Kerlan, R.; Merle, P.; O''Neil, B.; Poon, R.; Schwartz, L.; Tepper, J.; Yao, F.; Haller, D.; Mooney, M.; Venook, A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010 Sep 1;28(25):3994-4005.

    Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11.

    Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-955-8781
    Appointment Phone: 410-955-8964
    Fax: 410-614-1005
    Location Map

    Department/Division

    • Oncology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer